Inclusive Capital Partners, led by activist investor Jeff Ubben, is reportedly seeking to sell its stake in Bayer AG, three years after first disclosing the investment. The move signals a potential shift in the firm’s portfolio strategy, as it aims to capitalize on market conditions or reallocate capital. Bayer, a global pharmaceutical giant, has seen its share price fluctuate amid regulatory and competitive pressures, making it a target for strategic exits.

While the exact valuation of the stake remains undisclosed, the sale could impact Bayer’s ownership structure and investor confidence. Analysts note that such a move by an activist firm often precedes broader market adjustments, particularly in sectors facing regulatory scrutiny or innovation challenges.